Using data for 25,780 species categorized on the International Union for Conservation of Nature Red List, we present an assessment of the status of the world’s vertebrates. One-fifth of species are classified as Threatened, and we show that this figure is increasing: On average, 52 species of mammals, birds, and amphibians move one category closer to extinction each year. However, this overall pattern conceals the impact of conservation successes, and we show that the rate of deterioration would have been at least one-fifth again as much in the absence of these. Nonetheless, current conservation efforts remain insufficient to offset the main drivers of biodiversity loss in these groups: agricultural expansion, logging, overexploitation, and invasive alien species

2016-12-23T18:52:10

We surveyed the population status of the Neotropical toad genus Atelopus, and document recent catastrophic declines that are more severe than previously reported for any amphibian genus. Of 113 species that have been described or are candidates for description, data indicate that in 42 species, population sizes have been reduced by at least half and only ten species have stable populations. The status of the remaining taxa is unknown. At least 30 species have been missing from all known localities for at least 8 yr and are feared extinct. Most of these species were last seen between 1984 and 1996. All species restricted to elevations of above 1000 m have declined and 75 percent have disappeared, while 58 percent of lowland species have declined and 38 percent have disappeared. Habitat loss was not related to declines once we controlled for the effects of elevation. In fact, 22 species that occur in protected areas have disappeared. The fungal disease Batrachochytrium dendrobatidis has been documented from nine species that have declined, and may explain declines in higher elevation species that occur in undisturbed habitats. Climate change may also play a role, but other potential factors such as environmental contamination, trade, and introduced species are unlikely to have affected more than a handful of species. Widespread declines and extinctions in Atelopus may reflect population changes in other Neotropical amphibians that are more difficult to survey, and the loss of this trophic group may have cascading effects on other species in tropical ecosystems. RESUMENExaminamos el estado poblacional de las ranas neotropicales del género Atelopus y documentamos disminuciones catastróficas recientes, las más drásticas señaladas para cualquier género de anfibios. De las 113 especies que han sido descritas o son candidatas para ser descritas, los datos poblacionales indican que en 42 especies, las poblaciones han sido reducidas por lo menos a la mitad y solamente diez especies tienen poblaciones estables. El estado de los taxa restantes es desconocido. Por lo menos 30 especies no han sido vistas en al menos ocho años de todas las localidades conocidas, y se teme que se hayan extinguido La mayoría de estas especies desaparecieron entre 1984 y 1996. Todas las especies con SPECIAL SECTION Declines and Extinctions of Atelopus 191rangos altitudinales de 1000 m o superiores han sufrido disminuciones poblacionales, el 75 por ciento de estas ha desaparecido del todo. El 58 por ciento de las especies de bajura han sufrido disminuciones, mientras que el 38 por ciento ha desaparecido del todo. La pérdida de hábitat, no fue relacionada con las disminuciones una vez que se controló el efecto de altura en los análisis. De hecho, unas 22 especies que tienen poblaciones dentro deáreas protegidas han desaparecido. El hongo quítrido Batrachochytrium dendrobatidis estuvo presente en nueve especies que han experimentado disminuciones y puede explicar desapariciones en especies que ocupan hábitats no perturbados a mayores elevac...

No abstract

Vitamin D has shown to play a role in multiple diseases due to its skeletal and extraskeletal actions. Furthermore, vitamin D deficiency has become a worldwide health issue. Few supplementation guidelines mention calcifediol treatment, despite being the direct precursor of calcitriol and the biomarker of vitamin D status. This 1-year, phase III-IV, double-blind, randomized, controlled, multicenter clinical trial assessed the efficacy and safety of calcifediol 0.266 mg soft capsules in vitamin D-deficient postmenopausal women, compared to cholecalciferol. Results reported here are from a prespecified interim analysis, for the evaluation of the study's primary endpoint: the percentage of patients with serum 25-hydroxyvitamin D (25(OH)D) levels above 30 ng/ml after 4 months. A total of 303 patients were enrolled, of whom 298 were included in the intention-to-treat (ITT) population. Patients with baseline levels of serum 25(OH)D <20 ng/ml were randomized 1:1:1 to calcifediol 0.266 mg/month for 12 months, calcifediol 0.266 mg/month for 4 months followed by placebo for 8 months, and cholecalciferol 25,000 IU/month for 12 months. At month 4, 35.0% of postmenopausal women treated with calcifediol and 8.2% of those treated with cholecalciferol reached serum 25(OH)D levels above 30 ng/ml (p < 0.0001). The most remarkable difference between both drugs in terms of mean change in serum 25(OH)D levels was observed after the first month of treatment (mean AE standard deviation change = 9.7 AE 6.7 and 5.1 AE 3.5 ng/ml in patients treated withThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.